Gaudium IVF & Women Health has announced a groundbreaking development in India's fertility healthcare sector with the introduction of artificial intelligence-led infertility treatment. This milestone represents an industry first in the country, coming just one month after the company became India's first publicly listed IVF chain.

AI-Driven Technology Integration

The development involves the integration of advanced AI-driven embryology systems into routine clinical practice. The company has introduced two key technologies:

The milestone was formally inaugurated by Hon'ble Union Minister Shri Nitin Jairam Gadkari, Minister for Road Transport and Highways, Government of India, on April 1st, 2026.

Strategic Partnership with IVF 2.0

This integration has been undertaken in collaboration with IVF 2.0, a UK-headquartered embryology innovation organisation founded by renowned embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. The partnership brings globally advanced embryology intelligence into the Indian clinical ecosystem.

Giles Palmer, Clinical Scientist and Director of Global Communications at IVF 2.0, stated: "Our focus has always been to translate embryology intelligence into measurable clinical outcomes. Partnering with Gaudium IVF allows us to bring our AI-driven solutions into a high-growth market like India and set new benchmarks for how reproductive medicine is practised."

Technology Capabilities and Clinical Impact

The newly introduced technologies are designed to enhance critical stages of the IVF process:

SiD (Sperm Identification Device) analyses various sperm movement parameters to identify the most viable sperm for fertilisation, potentially leading to better-quality blastocyst formation.

ERICA (Embryo Ranking Intelligent Classification Assistant) provides objective, data-driven ranking of embryos by analysing static images of blastocysts based on key morphological and developmental characteristics.

These non-invasive tools assist embryologists in improving decision-making and reducing variability. Early clinical observations suggest that the integration of these AI systems can significantly improve fertilisation and blastocyst development rates.

Leadership Perspectives

Hon'ble Union Minister Shri Nitin Jairam Gadkari remarked at the inauguration: "The adoption of advanced technologies such as artificial intelligence reflects India's growing strength in innovation. Initiatives like these will play an important role in shaping the future of technology-led solutions across sectors."

Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF, commented: "Fertility care is entering a new era where precision and intelligence will define outcomes. By integrating AI into infertility treatment, Gaudium IVF is not only improving success rates but also bringing greater predictability, transparency, and trust to the patient journey."

Expected Benefits

By improving precision and consistency, the adoption of AI has the potential to:

• Reduce the need for repeat cycles
• Lower the emotional, physical, and financial burden on patients
• Inspire confidence among clinicians and stakeholders
• Enhance overall treatment success rates

Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility care provider with a PAN India presence and growing global reach. The organisation continues to push the boundaries of reproductive healthcare innovation in the country, reinforcing its position as an industry pioneer under the leadership of Manika Khanna.

Gaudium IVF & Women Health Limited has informed stock exchanges about arbitration proceedings filed against the company by Neomile Corporate Advisory Limited, seeking ₹29,20,50,000 for alleged advisory services related to its Initial Public Offering.

Arbitration Details

The arbitration petition has been filed under Section 9 of the Arbitration & Conciliation Act, 1996, before the High Court of Judicature at Bombay Ordinary Original Civil Jurisdiction Commercial Arbitration. The petitioner is seeking interim measures of protection for the claimed amount.

Company's Response

Gaudium IVF has categorically rejected the claims made by Neomile Corporate Advisory Limited. The company has stated that the petition is frivolous, unsubstantiated, and premised on fundamental factual misstatements that are contrary to overwhelming facts and evidence.

The company has assured that it is taking requisite steps to safeguard its interests in this matter. The disclosure was made in accordance with Regulation 30 of SEBI Listing Regulations and SEBI circular dated July 13, 2023.

Legal Framework

The arbitration proceedings relate to an alleged arrangement for advisory services in connection with the company's IPO. Neomile Corporate Advisory Limited claims entitlement to the specified amount under this purported arrangement.

The company received a legal notice from M/s. Desai & Diwanji, Advocates, representing Neomile Corporate Advisory Limited, before the formal arbitration petition was filed. The matter involves commercial arbitration jurisdiction at the Bombay High Court.

Regulatory Compliance

The disclosure has been made under the mandatory requirements of SEBI regulations for listed companies. Gaudium IVF has also placed this information on its official website as required by regulatory guidelines. The company secretary Naveen Kumar signed the disclosure document on April 01, 2026.